Navigation Links
GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

CHICAGO, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC), ovarian cancer and soft tissue sarcoma (STS). These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.

Pazopanib is an oral, investigational angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit, important proteins in the angiogenic process. Angiogenesis, which is the growth of new blood vessels in the body, plays a critical role in the growth and spread of tumors. (1,2)

Renal cell carcinoma study (Abstract 5031) (3)

This ongoing Phase II randomized discontinuation study is evaluating patients with advanced or metastatic RCC who have not received prior systemic therapy or have failed one prior therapy (cytokine or bevacizumab-containing regimen). All patients received 800 mg of pazopanib taken orally, once-daily during a 12 week lead-in period. Based on data available on 60 patients at the time of a planned interim analysis, the Independent Data Monitoring Committee (IDMC) recommended that randomization to placebo for patients with stable disease should be discontinued. The study continued as an open-label, single- arm study with all patients receiving pazopanib.

The preliminary week 12 response rate for all 225 patients was 27%. In addition, stable disease was achieved in 46% of patients for a total disease control rate of 73%. Responses have been observed beyond week 12, and the overall response rate will be reported at study completion. Response was determined according to RECIST (Response Evaluation Criteria In Solid Tumors) which is a set of published rules that defines when
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:8/4/2015)... New York , August 4, 2015 ... report titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, ... and Others) - Global Industry Analysis, Size, Volume, Share, ... According to a new market report published by ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ...
(Date:8/4/2015)... BioElectronics Corporation (OTC Pink: BIEL), the ... medical devices, announced today that its registry study ... device has been published in the prominent peer ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain sufferers ... Chronic pain is a major ...
(Date:8/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ) has announced the ... (Household & Personal Care, Pharmaceutical, Oilfield, Agrochemicals, and Others) ... report to their offering. The market ... in 2014 and is projected to grow at a ... data mentioned in the report is based on the ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3
... America,s Specialty Medicines Companies (ASMC), an informal working group ... concerns about H.R. 3962, the "Affordable Health Care for ... These smaller companies fear that the cumulative effect of ... their efforts to bring new medicines to market. ...
... Nov. 6 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... President and Chief Financial Officer, effective November 9, 2009. ... Team updates. , "Michael will be an excellent complement ...
Cached Medicine Technology:Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5
(Date:8/4/2015)... ... August 04, 2015 , ... Many men are confused about the ... Man™ is standing up as a voice of authority for men seeking accurate information ... industry with special experience and expertise in the safe and effective treatment of low ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... checking with “Dr. Google” before calling a physician. In an effort to share ... first health care provider in Pennsylvania to publicly share patient satisfaction ratings and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mesothelioma researchers in ... back: Retreatment may be a viable option. Surviving Mesothelioma has just posted an ... According to surgeons at the University of New South Wales, peritoneal mesothelioma ...
(Date:8/4/2015)... Nevada (PRWEB) , ... August 04, 2015 , ... ... a striking contemporary look at unique artistic expressions from a diverse group of ... the Life Is Beautiful Music & Art Festival on September 25-27, 2015 in ...
(Date:8/4/2015)... New York, NY (PRWEB) , ... August 04, ... ... FHA multifamily mortgage lender specializing in healthcare finance, announced the closing of a ... operates a two campus health system located in Smithfield and Clayton, North Carolina. ...
Breaking Medicine News(10 mins):Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3
... SMITHFIELD, R.I., July 29 FGX International,(Nasdaq: FGXI ... sunglasses and costume jewelry, today announced financial results,for its ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071025/NETH104LOGO ), ... sales increased 14% to $71.6 million in the current ...
... WHITE PLAINS, N.Y., July 29 Four leaders,from the ... been elected to the national Board of Trustees of ... March of Dimes trustees, who serve as volunteers, represent ... and serve five-year,terms., The new trustees are:, ...
... cancer screening program in Norway and an approach to ... are equally sensitive for detecting cancer, researchers report in ... of the National Cancer Institute . But the recall ... Breast cancer screening in the United States is usually ...
... Income Per Share, SAN JOSE, Calif., July 29 ... leading provider of medical devices,for the minimally invasive treatment ... second quarter ended June 30, 2008., Net revenues ... $31.9,million compared with $17.2 million for the second quarter ...
... (Pink,Sheets: VSMD) announced today that Craig M. Walker, M.D., ... the number of directors from,four to five. Dr. Walker ... cardiologist, clinical investigator and thought leader., "Dr. Walker ... one of the,world,s leading experts in the care of ...
... literacy and,curbing HIV/AIDS is the centerpiece of the U.S. ... stabilize parts of,Haiti plagued by community unrest., The ... -- will,target public and private primary schools as well ... who manages a worldwide education and,health program for USAID., ...
Cached Medicine News:Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 2Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 3Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 4Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 5Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 6Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 7Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 8Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 9Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 10Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 11Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 12Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 13Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 14Health News:Four Named to March of Dimes Board of Trustees 2Health News:Four Named to March of Dimes Board of Trustees 3Health News:Four Named to March of Dimes Board of Trustees 4Health News:Four Named to March of Dimes Board of Trustees 5Health News:Four Named to March of Dimes Board of Trustees 6Health News:Four Named to March of Dimes Board of Trustees 7Health News:2 different breast cancer screening strategies are equally effective 2Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 2Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 3Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 4Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 5Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 6Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 7Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 8Health News:VASAMED(R) Appoints Craig M. Walker, MD to Board of Directors 2Health News:Three Rs and HIV/AIDS Mark New Haiti Literacy Plan 2
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours....
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
Medicine Products: